#United States #San Diego #Class Action #Investor Lawsuit #PROCEPT BioRobotics

Investors of PROCEPT BioRobotics Class Action Alert

Robbins Geller Rudman & Dowd LLP has announced an important opportunity for those who purchased common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) from February 28, 2024, until February 25, 2026. Shareholders who suffered significant losses during this period are encouraged to step forward for the chance to lead a class action lawsuit against the company, with a deadline set for September 22, 2026.

This class action is primarily centered around allegations that current and former executives of PROCEPT violated the Securities Exchange Act of 1934. The lawsuit, titled Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, accuses the company of making misleading statements that concealed critical adverse facts about its business operations and financial health.

Allegations Against PROCEPT

Investors should be aware that the lawsuit points to several serious claims including:
1. Undisclosed Discount Programs: Throughout the class period, PROCEPT reportedly employed a significant discount program, which led customers to place larger orders than the actual procedural demand could support. This practice raised questions about the sustainability of the company's sales volumes.
2. Inflated Sales Figures: The undisclosed incentives artificially boosted reported sales figures, pulling future sales into the present, potentially jeopardizing the company’s ability to sustain that level of sales moving forward.
3. Excess Inventory Concerns: The mismatch between reported sales figures and actual procedural demand resulted in an inventory surplus, with estimates indicating an excess of over 10,000 handpiece units by the end of the class period.
4. Operational Risks: These strategies exposed the company to unrecognized operational risks, bringing into question its ability to meet future sales projections.

Significant Stock Price Declines

The allegations came to a head during the company’s quarterly earnings announcements:

• - On August 6, 2025, PROCEPT disclosed a dramatic reduction in anticipated handpiece sales. Stock prices dropped about 16% in the following trading days.
• - Following further disappointing sales results and adjustments to guidance on November 4, 2025, the company's stock faced another significant decline, plummeting over 10%.

As the trial progresses, the revelations surrounding PROCEPT’s financial conduct have raised serious concerns among investors who trusted the company’s growth narrative.

How to Participate in the Class Action

Investors who believe they qualify to lead the class action lawsuit must act quickly. The process allows any investor who acquired PROCEPT common stock during the specified class period to apply for the lead plaintiff position, which involves representing the interests of the shareholder group at large.

For individuals looking to join the class action, it is crucial to submit an interest form through the law firm’s website or contact the attorneys directly at Robbins Geller. Their expertise in managing such investor lawsuits can significantly impact the outcome for the participants involved.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a well-regarded law firm, known for its successful track record in securities fraud cases and shareholder rights. They have demonstrated excellence in recovering funds for investors, ranking #1 for securities class action recoveries in recent years.

This ongoing case against PROCEPT BioRobotics serves as a crucial reminder for investors to remain vigilant and informed about potential risks associated with their investments. With the deadline for appointing a lead plaintiff fast approaching, those affected should act without delay to protect their rights and seek justice for their financial losses.